The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
George A Calin - One of the best experts on this subject based on the ideXlab platform.
-
Long noncoding RNA in prostate bladder and kidney cancer
European Urology, 2014Co-Authors: Elena S Martensuzunova, Rene Bottcher, Carlo M Croce, Guido Jenster, Tapio Visakorpi, George A CalinAbstract:Context: Genomic regions without protein-coding potential give rise to millions of protein-noncoding RNA transcripts (noncoding RNA) that participate in virtually all cellular processes. Research over the last 10 yr has accumulated evidence that Long noncoding RNAs (lncRNAs) are often altered in human urologic cancers. Objective: To review current progress in the biology and implication of lncRNAs associated with prostate, bladder, and kidney cancer. Evidence acquisition: The PubMed database was searched for articles in the English language with combinations of the Medical Subject Headings terms Long non coding RNA, Long noncoding RNA, Long Untranslated RNA, cancer, neoplasms, prostate, bladder, and kidney. Evidence synthesis: We summarise existing knowledge on the systematics, biology, and function of lncRNAs, particularly these involved in prostate, kidney, and bladder cancer. We also discuss the possible utilisation of lncRNAs as novel biomarkers and potential therapeutic targets in urologic malignancies and portray the major challenges and future perspectives of ongoing lncRNA research. Conclusions: LncRNAs are important regulators of gene expression interacting with the major pathways of cell growth, proliferation, differentiation, and survival. Alterations in the function of lncRNAs promote tumour formation, progression, and metastasis of prostate, bladder, and kidney cancer. LncRNAs can be used as noninvasive tumour markers in urologic malignancies. Increased knowledge of the molecular mechanisms by which lncRNAs perform their function in the normal and malignant cell will lead to a better understanding of tumour biology and could provide novel therapeutic targets for the treatment of urologic cancers. Patient summary: In this paper we reviewed current knowledge of Long noncoding RNAs (lncRNAs) for the detection and treatment of urologic cancers. We conclude that lncRNAs can be used as novel biomarkers in prostate, kidney, or bladder cancer. LncRNAs hold promise as future therapeutic targets, but more research is needed to gain a better understanding of their biologic function.
Rene Bottcher - One of the best experts on this subject based on the ideXlab platform.
-
Long noncoding RNA in prostate bladder and kidney cancer
European Urology, 2014Co-Authors: Elena S Martensuzunova, Rene Bottcher, Carlo M Croce, Guido Jenster, Tapio Visakorpi, George A CalinAbstract:Context: Genomic regions without protein-coding potential give rise to millions of protein-noncoding RNA transcripts (noncoding RNA) that participate in virtually all cellular processes. Research over the last 10 yr has accumulated evidence that Long noncoding RNAs (lncRNAs) are often altered in human urologic cancers. Objective: To review current progress in the biology and implication of lncRNAs associated with prostate, bladder, and kidney cancer. Evidence acquisition: The PubMed database was searched for articles in the English language with combinations of the Medical Subject Headings terms Long non coding RNA, Long noncoding RNA, Long Untranslated RNA, cancer, neoplasms, prostate, bladder, and kidney. Evidence synthesis: We summarise existing knowledge on the systematics, biology, and function of lncRNAs, particularly these involved in prostate, kidney, and bladder cancer. We also discuss the possible utilisation of lncRNAs as novel biomarkers and potential therapeutic targets in urologic malignancies and portray the major challenges and future perspectives of ongoing lncRNA research. Conclusions: LncRNAs are important regulators of gene expression interacting with the major pathways of cell growth, proliferation, differentiation, and survival. Alterations in the function of lncRNAs promote tumour formation, progression, and metastasis of prostate, bladder, and kidney cancer. LncRNAs can be used as noninvasive tumour markers in urologic malignancies. Increased knowledge of the molecular mechanisms by which lncRNAs perform their function in the normal and malignant cell will lead to a better understanding of tumour biology and could provide novel therapeutic targets for the treatment of urologic cancers. Patient summary: In this paper we reviewed current knowledge of Long noncoding RNAs (lncRNAs) for the detection and treatment of urologic cancers. We conclude that lncRNAs can be used as novel biomarkers in prostate, kidney, or bladder cancer. LncRNAs hold promise as future therapeutic targets, but more research is needed to gain a better understanding of their biologic function.
Elena S Martensuzunova - One of the best experts on this subject based on the ideXlab platform.
-
Long noncoding RNA in prostate bladder and kidney cancer
European Urology, 2014Co-Authors: Elena S Martensuzunova, Rene Bottcher, Carlo M Croce, Guido Jenster, Tapio Visakorpi, George A CalinAbstract:Context: Genomic regions without protein-coding potential give rise to millions of protein-noncoding RNA transcripts (noncoding RNA) that participate in virtually all cellular processes. Research over the last 10 yr has accumulated evidence that Long noncoding RNAs (lncRNAs) are often altered in human urologic cancers. Objective: To review current progress in the biology and implication of lncRNAs associated with prostate, bladder, and kidney cancer. Evidence acquisition: The PubMed database was searched for articles in the English language with combinations of the Medical Subject Headings terms Long non coding RNA, Long noncoding RNA, Long Untranslated RNA, cancer, neoplasms, prostate, bladder, and kidney. Evidence synthesis: We summarise existing knowledge on the systematics, biology, and function of lncRNAs, particularly these involved in prostate, kidney, and bladder cancer. We also discuss the possible utilisation of lncRNAs as novel biomarkers and potential therapeutic targets in urologic malignancies and portray the major challenges and future perspectives of ongoing lncRNA research. Conclusions: LncRNAs are important regulators of gene expression interacting with the major pathways of cell growth, proliferation, differentiation, and survival. Alterations in the function of lncRNAs promote tumour formation, progression, and metastasis of prostate, bladder, and kidney cancer. LncRNAs can be used as noninvasive tumour markers in urologic malignancies. Increased knowledge of the molecular mechanisms by which lncRNAs perform their function in the normal and malignant cell will lead to a better understanding of tumour biology and could provide novel therapeutic targets for the treatment of urologic cancers. Patient summary: In this paper we reviewed current knowledge of Long noncoding RNAs (lncRNAs) for the detection and treatment of urologic cancers. We conclude that lncRNAs can be used as novel biomarkers in prostate, kidney, or bladder cancer. LncRNAs hold promise as future therapeutic targets, but more research is needed to gain a better understanding of their biologic function.
A. M. Korotkova - One of the best experts on this subject based on the ideXlab platform.
-
Functional analysis of the Xist promoter region in mouse Mus musculus
Russian Journal of Genetics, 2011Co-Authors: A. M. Korotkova, E. A. Elisaphenko, Suren M. ZakianAbstract:X-chromosome inactivation which takes place in early embryogenesis of all higher mammals is largely determined by the Xist gene activity. This gene encodes Long Untranslated RNA, which provides transcriptional silencer of the genes on chromosome. In the present study, three enhancer and three silencer transcriptional elements were identified in the Xist promoter region. In these regions, location of putative transcription factors was demonstrated, including the ER site, which was discovered in two positions. The effect of estradiol and retinoic acid on the promoter activity was investigated. The estradiol-induced increase of the promoter activity was demonstrated. A model of the estrogen effect on X chromosome inactivation was suggested.
-
Functional analysis of the Xist promoter region in mouse Mus musculus
Genetika, 2011Co-Authors: A. M. Korotkova, E A Elisafenko, S M ZakiianAbstract:X-chromosome inactivation which takes place in early embryogenesis of all higher mammals is largely determined by the Xist gene activity. This gene encodes Long Untranslated RNA, which provides transcriptional silencing of the genes on chromosome. In the present study, three enhancer and three silencing transcriptional elements were identified in the Xist promoter region. In these regions, location of putative transcription factors was demonstrated, including the ER site, which was discovered in two positions. The effect of estradiol and retinoic acid on the promoter activity was investigated. The estradiol-induced increase of the promoter activity was demonstrated. A model of the estrogen effect on X chromosome inactivation was suggested.
Carlo M Croce - One of the best experts on this subject based on the ideXlab platform.
-
Long noncoding RNA in prostate bladder and kidney cancer
European Urology, 2014Co-Authors: Elena S Martensuzunova, Rene Bottcher, Carlo M Croce, Guido Jenster, Tapio Visakorpi, George A CalinAbstract:Context: Genomic regions without protein-coding potential give rise to millions of protein-noncoding RNA transcripts (noncoding RNA) that participate in virtually all cellular processes. Research over the last 10 yr has accumulated evidence that Long noncoding RNAs (lncRNAs) are often altered in human urologic cancers. Objective: To review current progress in the biology and implication of lncRNAs associated with prostate, bladder, and kidney cancer. Evidence acquisition: The PubMed database was searched for articles in the English language with combinations of the Medical Subject Headings terms Long non coding RNA, Long noncoding RNA, Long Untranslated RNA, cancer, neoplasms, prostate, bladder, and kidney. Evidence synthesis: We summarise existing knowledge on the systematics, biology, and function of lncRNAs, particularly these involved in prostate, kidney, and bladder cancer. We also discuss the possible utilisation of lncRNAs as novel biomarkers and potential therapeutic targets in urologic malignancies and portray the major challenges and future perspectives of ongoing lncRNA research. Conclusions: LncRNAs are important regulators of gene expression interacting with the major pathways of cell growth, proliferation, differentiation, and survival. Alterations in the function of lncRNAs promote tumour formation, progression, and metastasis of prostate, bladder, and kidney cancer. LncRNAs can be used as noninvasive tumour markers in urologic malignancies. Increased knowledge of the molecular mechanisms by which lncRNAs perform their function in the normal and malignant cell will lead to a better understanding of tumour biology and could provide novel therapeutic targets for the treatment of urologic cancers. Patient summary: In this paper we reviewed current knowledge of Long noncoding RNAs (lncRNAs) for the detection and treatment of urologic cancers. We conclude that lncRNAs can be used as novel biomarkers in prostate, kidney, or bladder cancer. LncRNAs hold promise as future therapeutic targets, but more research is needed to gain a better understanding of their biologic function.
